Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma

Thalidomide developed in 1954 for morning sickness had proven to be a teratogen and hence was withdrawn from market. Resurgence of thalidomide began as an immunomodulator when it was shown to be effective in the management of multiple myeloma and many conditions like erythema nodosum leprosum, graft...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Anupam, Sil, Amrita, Mishra, Vivek, Das, Nilay Kanti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Drug Watch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175899/
https://www.ncbi.nlm.nih.gov/pubmed/25298592
http://dx.doi.org/10.4103/0253-7613.140598
Descripción
Sumario:Thalidomide developed in 1954 for morning sickness had proven to be a teratogen and hence was withdrawn from market. Resurgence of thalidomide began as an immunomodulator when it was shown to be effective in the management of multiple myeloma and many conditions like erythema nodosum leprosum, graft versus host disease, recurrent aphthous ulcers etc. We report a case of Stevens Johnson syndrome-toxic epidermal necrolysis developing in an elderly male who was prescribed thalidomide after being diagnosed with multiple myeloma.

Ejemplares similares